65. Primary immunodeficiency Clinical trials / Disease details
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03080480 (ClinicalTrials.gov) | September 1, 2017 | 27/2/2017 | Pioglitazone Therapy for Chronic Granulomatous Disease | Efficacy and Safety of Pioglitazone Therapy for Chronic Granulomatous Disease Patients With Severe Infection. | Chronic Granulomatous Disease | Drug: Pioglitazone | Children's Hospital of Fudan University | NULL | Terminated | 1 Month | 18 Years | All | 3 | Phase 1/Phase 2 | China |
| 2 | NCT02733679 (ClinicalTrials.gov) | September 29, 2016 | 31/3/2016 | Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone | Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone | Ataxia-Telangiectasia | Drug: Metformin;Drug: Pioglitazone | NHS Tayside | University of Dundee | Completed | 18 Years | 30 Years | All | 27 | Phase 4 | United Kingdom |